If you or a loved one is taking Tysabri and experiencing new neurological symptoms like confusion, vision changes, or weakness, you may be concerned about progressive multifocal leukoencephalopathy (PML). This concern is grounded in a long history of post-marketing surveillance and clinical research that has identified specific symptom patterns associated with PML in Tysabri-treated patients. This page reviews the clinical signals documented in published reports and FDA labeling to help you understand the evidence.
From this general health perspective, the transition to occupational exposure concerns is straightforward. For individuals who have received certain therapies and subsequently developed serious complications, the question of legal recourse arises. This pivot moves from population-level risk communication to individual circumstances, where exposure to a specific medication may lead to significant health consequences. The focus now turns to the practical implications of such exposure, including the role of legal professionals in addressing cases of alleged harm. Tysabri (natalizumab) is a biologic medication approved for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of developing Progressive Multifocal Leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus.
The United States Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently placed at the beginning of the prescribing information to alert healthcare professionals and patients to the serious nature of this risk. The clinical presentation of PML can be subtle and may initially mimic symptoms of multiple sclerosis, making early diagnosis challenging. Common symptoms include progressive weakness on one side of the body, clumsiness, visual disturbances, and changes in thinking, memory, and orientation. As the infection spreads in the brain, it can lead to severe disability and death. Diagnosis typically involves brain magnetic resonance imaging (MRI) showing characteristic lesions, detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction (PCR), and sometimes brain biopsy. The FDA's boxed warning emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The mechanistic pathway linking Tysabri to PML involves the drug's action on the immune system. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing them from crossing the blood-brain barrier into the central nervous system. This reduces inflammation in the brain, which is beneficial for treating multiple sclerosis, but it also impairs immune surveillance against the JC virus. In immunocompromised individuals, the JC virus can reactivate and cause PML. The FDA has identified three specific risk factors for developing PML in Tysabri-treated patients: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with longer treatment duration, especially beyond two years.
The FDA Adverse Event Reporting System (FAERS) database contains numerous reports of adverse events associated with Tysabri. While PML is the most serious, other frequently reported events include fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the need for careful monitoring of patients on Tysabri for any new or worsening neurological symptoms that could indicate PML. The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning is explicit about the risk, but questions may arise about whether patients and healthcare providers were adequately informed about the specific risk factors and the need for vigilant monitoring. The FDA requires that Tysabri be prescribed only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients are educated about the risks and that monitoring protocols are followed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients may develop PML, leading to severe outcomes. For patients who have developed PML after taking Tysabri, legal considerations may include whether the manufacturer provided sufficient warnings about the risk, whether the patient's specific risk factors were properly assessed, and whether the monitoring guidelines were followed.
The timeline between exposure to Tysabri and the development of PML can vary. In clinical trials, PML occurred in three patients: two with multiple sclerosis who had been treated for a median of 120 weeks, and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This indicates that PML can occur after varying durations of treatment, and patients who have been on Tysabri for longer periods, especially beyond two years, are at higher risk. In summary, Tysabri is associated with a well-documented risk of PML, a devastating brain infection. The FDA's boxed warning and the TOUCH program aim to mitigate this risk, but cases still occur. Patients who develop PML may face severe disability or death, and legal avenues may be available to seek compensation for harm. It is essential for affected individuals to consult with an attorney experienced in pharmaceutical litigation to understand their rights and options.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic medication approved for the treatment of multiple sclerosis and Crohn's disease. It works by binding to alpha-4 integrins on immune cells, preventing them from crossing the blood-brain barrier, which reduces inflammation in the brain.
PML is a severe opportunistic viral infection of the brain caused by the JC virus. It usually leads to death or severe disability. Symptoms include progressive weakness, clumsiness, visual disturbances, and changes in thinking, memory, and orientation.
The FDA has identified three risk factors: the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk.
You should seek immediate medical attention. The FDA advises that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML. Your doctor will likely perform an MRI and test for JC virus DNA in cerebrospinal fluid.
Legal avenues may be available to seek compensation for harm. It is essential to consult with an attorney experienced in pharmaceutical litigation to understand your rights and options, especially regarding whether the manufacturer provided sufficient warnings.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.